Harbor Capital Advisors Inc. Invests $390,000 in TCR2 Therapeutics Inc. (NASDAQ:TCRR)

Harbor Capital Advisors Inc. bought a new position in shares of TCR2 Therapeutics Inc. (NASDAQ:TCRRGet Rating) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 83,619 shares of the company’s stock, valued at approximately $390,000.

Other large investors have also added to or reduced their stakes in the company. Moors & Cabot Inc. purchased a new position in shares of TCR2 Therapeutics during the third quarter valued at $25,000. Macquarie Group Ltd. purchased a new position in shares of TCR2 Therapeutics during the third quarter valued at $30,000. BNP Paribas Arbitrage SA increased its stake in shares of TCR2 Therapeutics by 126.6% during the third quarter. BNP Paribas Arbitrage SA now owns 7,831 shares of the company’s stock valued at $67,000 after buying an additional 4,375 shares during the period. Marquette Asset Management LLC purchased a new position in shares of TCR2 Therapeutics during the fourth quarter valued at $93,000. Finally, Point72 Hong Kong Ltd increased its stake in shares of TCR2 Therapeutics by 557.3% during the third quarter. Point72 Hong Kong Ltd now owns 11,023 shares of the company’s stock valued at $94,000 after buying an additional 9,346 shares during the period. Institutional investors and hedge funds own 80.16% of the company’s stock.

NASDAQ TCRR traded up $0.11 during trading on Tuesday, hitting $2.49. The company’s stock had a trading volume of 10,487 shares, compared to its average volume of 623,761. The company has a market cap of $95.98 million, a PE ratio of -0.90 and a beta of 2.26. The business’s 50 day simple moving average is $2.71 and its 200-day simple moving average is $4.49. TCR2 Therapeutics Inc. has a fifty-two week low of $2.33 and a fifty-two week high of $25.22.

TCR2 Therapeutics (NASDAQ:TCRRGet Rating) last released its earnings results on Tuesday, March 22nd. The company reported ($0.72) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.01. On average, research analysts forecast that TCR2 Therapeutics Inc. will post -2.95 earnings per share for the current fiscal year.

Several research firms have issued reports on TCRR. Piper Sandler cut their target price on TCR2 Therapeutics from $26.00 to $23.00 in a research note on Tuesday, March 22nd. Zacks Investment Research lowered TCR2 Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 18th. HC Wainwright cut their target price on TCR2 Therapeutics from $25.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, January 13th. Finally, The Goldman Sachs Group lowered TCR2 Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $28.00 to $5.00 in a research note on Wednesday, January 19th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $17.39.

TCR2 Therapeutics Company Profile (Get Rating)

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

Featured Articles

Want to see what other hedge funds are holding TCRR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TCR2 Therapeutics Inc. (NASDAQ:TCRRGet Rating).

Institutional Ownership by Quarter for TCR2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.